Search
evinacumab-dgnb (Evkeeza)
Indications:
- homozygous familial hypercholesterolemia
Dosage:
8 mL 2.3 mL of 150 mg/mL
Adverse effects:
- common 10%
- nasopharyngitis
- less common (1-10%)
- flu-like symptoms (7%)
- infusion-related reactions (7%)
- dizziness (6%)
- rhinorrhea (5%)
- nausea (5%)
- extremity pain (4%)
- asthenia (4%)
- constipation (<3%)
- upper respiratory tract infection (<3%)
- nasal congestion (<3%)
- abdominal pain (<3%)
- other
- transient, mild-to-moderate decreased diastolic blood pressure
- increased heart rate
- serious
- anaphylaxis (1%)
Mechanism of action:
- recombinant human monoclonal Ab
- binds to & inhibits angiopoietin-like 3 (ANGPTL3) leading to decreased LDL-C, HDL-C, & triglycerides
- inhibition of ANGPTL3 induces accelerated hydrolysis of VLDL particles
- up-regulation of apolipoprotein-B containing lipoprotein clearance
Interactions
drug adverse effects of anti-hyperlipidemic agents
General
anti-hyperlipidemic agent
pharmaceutical monoclonal antibody
References
- Styles S
FDA Approves Orphan Drug Evinacumab-dgnb for Homozygous FH
Medscape - Feb 11, 2021.
https://www.medscape.com/viewarticle/945719
- Raal FJ, Rosenson RS, Reeskamp LF
Evinacumab for Homozygous Familial Hypercholesterolemia
N Engl J Med. 2020 Aug 20;383(8):711-720
PMID: 32813947 Clinical Trial
https://www.nejm.org/doi/10.1056/NEJMoa2004215